Articles related to ATRIAL FIBRILLATION (AFIB)

In the randomized DECAF trial, patients undergoing cardioversion who consumed at least one caffeinated coffee daily experienced fewer clinically detected atrial fibrillation recurrences than those abstaining from caffeine. The study was modest in size and further validation is needed.

A randomized crossover trial of 108 habitual cannabis users found fewer premature atrial contractions on cannabis-use days than abstinence days. The short-term physiologic findings provide mechanistic insight but were not designed to evaluate long-term cardiovascular health outcomes.

Among more than 7,300 Swedish patients with Alzheimer’s disease and atrial fibrillation, NOAC use was associated with slower cognitive decline than warfarin or no anticoagulation. The observational findings did not establish causality but suggest potential differences in long-term cognitive outcomes.

In an observational target trial emulation of patients with atrial fibrillation and mitral stenosis, DOACs were associated with higher 1-year stroke risk than warfarin. Bleeding and all-cause mortality risks did not differ between groups.

A Medicare cohort study found a median delay of 494 days between incident heart failure diagnosis and ATTR-CM diagnosis, with female sex, aortic stenosis, COPD, coronary artery disease, diabetes, and hypertension associated with longer diagnostic delays.

The Heart Failure Society of America released a scientific statement establishing diagnostic criteria and a treatment framework for heart failure with mildly reduced ejection fraction, a phenotypically heterogeneous group historically underrepresented in dedicated interventional trials.